Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer
MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.
- Trial name
- NCT03799913
- Testing
- anti-MESO CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase II trial studies how well bevacizumab with or without fosbretabulin tromethamine works in treating patients with ovarian epithelial, fallopian tube, or peritoneal cavity cancer that has come back or is…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT01305213
- Testing
- Bevacizumab, Fosbretabulin Tromethamine, Laboratory Biomarker Analysis
- Where
- 51 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Survival Outcomes
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
This is a phase II trial to explore efficacy and safety of niraparib in combination with anlotinib based on CA 125 level in newly diagnosed ovarian cancer.
- Conditions
- Ovarian Carcinoma, Survival Outcomes, Adverse Events, Niraparib
- Trial name
- NCT05311579
- Testing
- Niraparib plus anlotinib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Lei Li
Ovarian Neoplasms, Endometrial Neoplasms
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)
Multicenter, randomized, open-label, phase II clinical study comparing Dostarlimab +/- Bevacizumab with standard chemotherapy in patients with gynecological clear cell carcinoma.
- Conditions
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer
- Trial name
- DOVE (NCT06023862)
- Testing
- Dostarlimab, Bevacizumab, Doxorubicin
- Where
- 27 sites in Australia, Hong Kong and 5 more
- Volunteers
- 198 people
- Sponsor
- Yonsei University
Solid Organ Tumors
A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
The purpose of this research study is to collect information from patient's medical records that had a test called ChemoFx® ordered and to understand how doctors may have used the results of the ChemoFx® to treat patients with…
- Trial name
- NCT01271959
- Where
- 25 sites in United States
- Volunteers
- 167 people
- Sponsor
- Precision Therapeutics
Ovarian Cancer, Fallopian Tube Cancer
Study of Gemcitabine/Carboplatin/Bevacizumab to Treat Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The purpose of this study is to test the effectiveness, safety and tolerability of the drug combination: gemcitabine, carboplatin and bevacizumab in patients that have been diagnosed with platinum sensitive recurrent ovarian…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00267696
- Testing
- Bevacizumab, Gemcitabine, Carboplatin
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Breast Cancer, Cervical Cancer
Whole Body Hyperthermia Combined With Chemotherapy in Treating Patients With Metastatic Breast, Ovarian, Endometrial, or Cervical Cancer
RATIONALE: Hyperthermia therapy kills tumor cells by heating them to several degrees above body temperature. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Breast Cancer, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00003135
- Testing
- fluorouracil, pegylated liposomal doxorubicin hydrochloride, hyperthermia treatment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- The University of Texas Health Science Center, Houston
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Peritoneal Cancer, Ovarian Cancer
Second-line Intravenous Treatment For Recurrent Platinum-Sensitive Ovarian, Fallopian, Or Peritoneal Cancer
This research study was designed to determine the effectiveness of the drug, topotecan, given intravenously (into a vein) together with the drug gemcitabine in patients with recurrent platinum-sensitive ovarian, fallopian or…
- Conditions
- Peritoneal Cancer, Ovarian Cancer, Neoplasms, Ovarian, Fallopian Tube Cancer
- Trial name
- NCT00061308
- Testing
- Topotecan, Gemcitabine
- Where
- 19 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Ovarian Cancer Recurrent
Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer
This is a feasibility single-center study to investigate the tolerability, toxicity, quality of life, morbidity, mortality of the HIPEC treatment following cytoreductive surgery for treatment of recurrent ovarian, peritoneal, and…
- Trial name
- NCT03717610
- Testing
- radical surgery with HIPEC
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Uppsala University Hospital
Ovarian Carcinoma, Primary Peritoneal Carcinoma
Weekly Carboplatin/Docetaxel for Recurrent Ovarian/Peritoneal Cancer
The purpose of this study is to determine the safety and efficacy of this regimen in women with ovarian or peritoneal cancer
- Trial name
- NCT00214058
- Testing
- Carboplatin, Docetaxel
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Wisconsin, Madison
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
This phase II trial studies how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment.
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT03732950
- Testing
- Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 5 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: AMG 706 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00574951
- Testing
- motesanib diphosphate
- Where
- 19 sites in United States
- Volunteers
- 23 people
- Sponsor
- Gynecologic Oncology Group
Recurrent Platinum Resistant Ovarian Cancer
Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients
This study is a Phase I / Dose Expansion open label clinical study in patients with platinum-resistant epithelial ovarian cancer.
- Trial name
- OCTAVE (NCT02028117)
- Testing
- Enadenotucirev
- Where
- 8 sites in Spain, United Kingdom
- Volunteers
- 38 people
- Sponsor
- Akamis Bio
Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Ovarian Cancer
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
This clinical study will assess the safety and tolerability of escalating doses of mRNA-2416 alone and in combination with administered fixed doses of durvalumab in participants with relapsed/refractory solid tumor malignancies…
- Trial name
- NCT03323398
- Testing
- mRNA-2416, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 79 people
- Sponsor
- ModernaTX, Inc.
Platinum-resistant Ovarian Cancer
Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer
This is a randomized, double-blind Phase 3 study to compare the efficacy and safety of batiraxcept (AVB-S6-500) in combination with paclitaxel (PAC) versus placebo in combination with PAC in patients with platinum resistant…
- Trial name
- AXLerate-OC (NCT04729608)
- Testing
- Batiraxcept, Paclitaxel
- Where
- 150 sites in United States, Belgium and 9 more
- Volunteers
- 366 people
- Sponsor
- Aravive, Inc.
Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably.
- Conditions
- Colorectal Cancer, Constipation, Impaction, and Bowel Obstruction, Extrahepatic Bile Duct Cancer, Gastric Cancer
- Trial name
- NCT00004895
- Testing
- octreotide acetate
- Where
- United States
- Sponsor
- Northwestern University
Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer
This phase II trial studies how well olaparib with or without tremelimumab works in treating patients with ovarian, fallopian tube, or peritoneal cancer that has come back (recurrent).
- Conditions
- Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT04034927
- Testing
- Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
It is still not clear whether a positive AGO-score just selects patients with less aggressive biologic tumor behavior who as well would have had a positive outcome by chemotherapy only, or , if it is a score selecting patients…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- DESKTOPIII (NCT01166737)
- Testing
- Tumor Debulking Surgery (surgery in recurrent ovarian disease)
- Where
- 86 sites in Austria, Belgium and 10 more
- Volunteers
- 408 people
- Sponsor
- AGO Study Group
Solid Tumors
ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors
The purpose of this study is to determine the safety and tolerability of ME-344 when given in combination with Hycamtin® in patients with solid tumors
- Trial name
- NCT02100007
- Testing
- ME-344, Topotecan
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- MEI Pharma, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.